Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 4% Improvement Relative Risk Extubation 14% Ventilation time 27% c19early.org/j Alizadeh et al. Melatonin for COVID-19 RCT INTUBATED PATIENTS Is very late treatment with melatonin beneficial for COVID-19? Double-blind RCT 67 patients in Iran (June - September 2020) Improved recovery (p=0.19) and shorter ventilation (p=0.091), not stat. sig. Alizadeh et al., J. Taibah University Medical Sc.., doi:10.1016/j.jtumed.2022.04.012 Favors melatonin Favors control

High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial

Alizadeh et al., Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.04.012
Alizadeh et al., High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.04.012
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 67 extremely late stage intubated patients in Iran, showing lower CRP with melatonin treatment, but no significant difference in outcomes.
risk of death, 3.8% lower, RR 0.96, p = 0.73, treatment 28 of 33 (84.8%), control 30 of 34 (88.2%), NNT 30.
risk of no extubation, 13.6% lower, RR 0.86, p = 0.19, treatment 26 of 33 (78.8%), control 31 of 34 (91.2%), NNT 8.1.
ventilation time, 27.0% lower, relative time 0.73, p = 0.09, treatment 33, control 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alizadeh et al., 13 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 11 authors, study period June 2020 - September 2020.
Contact: h-hosami@sina.tums.ac.ir.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: JTUMED916_proof ■ 13 May 2022 ■ 1/7 Journal of Taibah University Medical Sciences (xxxx) xxx(xxx), xxx Taibah University Journal of Taibah University Medical Sciences www.sciencedirect.com 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 Original Article High dose melatonin as an adjuvant therapy in intubated patients with Q2 COVID-19: A randomized clinical trial Nafiseh Alizadeh a, Mehrnoush Dianatkhah b, Yousef Alimohamadi c, Hazhir Moradi d, Samaneh Akbarpour e, Majid Akrami f, Fariba Mansouri g, Neda Faraji g, Zahra Rezaie h, i i, Q3 Mahboubeh Alizadeh and Hadiseh Hosamirudsari * Q18 a Department of Pharmaceutical Care, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran Department of Clinical Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran c Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran Q4 d Medical School, Isfahan University of Medical Sciences, Isfahan, Iran Q5 e Occupational Sleep Research Center, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran f Department of Anesthesiology, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran g Department of Internal Medicine, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran h Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran i Department of Infectious Diseases, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran b Received 13 February 2022; revised 11 April 2022; accepted 28 April 2022; Available online - - - ‫ﺍﻟﻤﻠﺨﺺ‬ ‫ ﺍﻟﻤﻼﻳﻴﻦ ﻣﻦ ﺍﻟﻨﺎﺱ ﻓﻲ ﺟﻤﻴﻊ ﺃﻧﺤﺎﺀ‬19-‫ ﺃﺻﺎﺑﺖ ﺟﺎﺋﺤﺔ ﻛﻮﻓﻴﺪ‬:‫ﺃﻫﺪﺍﻑ ﺍﻟﺒﺤﺚ‬ ‫ ﻣﻦ ﺍﻟﻤﻌﺮﻭﻑ ﺃﻥ ﺟﺮﻋﺔ‬.‫ ﺗﺮﺟﻊ ﺍﻟﻮﻓﻴﺎﺕ ﺃﺳﺎﺳﺎ ﻟﺤﺎﻟﺔ ﺍﻻﻟﺘﻬﺎﺏ ﻭﻣﻀﺎﻋﻔﺎﺗﻪ‬.‫ﺍﻟﻌﺎﻟﻢ‬ ‫ ﻗﻴﻤﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺟﺮﻋﺔ‬.‫ﻋﺎﻟﻴﺔ ﻣﻦ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ ﺗﻌﺘﺒﺮ ﻋﺎﻣﻼ ﻣﻀﺎﺩﺍ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‬ ‫ﻋﺎﻟﻴﺔ ﻣﻦ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ ﻛﻌﻼﺝ ﻣﺴﺎﻋﺪ ﻓﻲ ﺍﻟﺤﺎﻻﺕ ﺍﻟﺤﺮﺟﺔ ﻟﻠﻤﺮﺿﻰ ﺍﻟﻤﺼﺎﺑﻴﻦ‬ .19-‫ﺑﻌﺪﻭﻯ ﻛﻮﻓﻴﺪ‬ ‫ ﻣﻠﻎ‬21 ‫ ﺃﺟﺮﻳﻨﺎ ﺗﺠﺮﺑﺔ ﺳﺮﻳﺮﻳﺔ ﻋﺸﻮﺍﺋﻴﺔ ﻣﺰﺩﻭﺟﺔ ﺍﻟﺘﻌﻤﻴﺔ ﻟﺠﺮﻋﺔ‬:‫ﻃﺮﻕ ﺍﻟﺒﺤﺚ‬ ‫ ﺗﻢ‬.19-‫ ﻣﺮﻳﻀﺎ ﻛﻮﻓﻴﺪ‬67 ‫ﻣﻦ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ ﻓﻲ ﺍﻟﻴﻮﻡ ﻣﻘﺎﺭﻧﺔ ﻣﻊ ﺩﻭﺍﺀ ﻭﻫﻤﻲ ﺑﻴﻦ‬ ‫ ﺍﻟﻤﻮﺛﻘﺔ‬19-‫ ﻋﺎﻣﺎ ﻭﺍﻟﻤﺼﺎﺑﻴﻦ ﺑﻌﺪﻭﻯ ﻛﻮﻓﻴﺪ‬18 ‫ﺍﻟﺘﺴﺠﻴﻞ ﻟﻠﻤﺮﺿﻰ ﺍﻷﻛﺒﺮ ﻣﻦ‬ ‫ ﺍﺳﺘﻤﺮ‬.‫ﻭﺍﻟﺬﻳﻦ ﺗﻢ ﺇﺩﺧﺎﻟﻬﻢ ﺇﻟﻰ ﻭﺣﺪﺓ ﺍﻟﻌﻨﺎﻳﺔ ﺍﻟﻤﺮﻛﺰﺓ ﻭﺧﻀﻌﻮﺍ ﻟﺘﻬﻮﻳﺔ ﻣﻴﻜﺎﻧﻴﻜﻴﺔ‬ .‫ﺇﻋﻄﺎﺀ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻮﻫﻤﻲ ﻟﻤﺪﺓ ﺧﻤﺴﺔ ﺃﻳﺎﻡ ﻣﻦ ﺧﻼﻝ ﺃﻧﺒﻮﺏ ﺃﻧﻔﻲ ﻣﻌﺪﻱ‬ ‫ ﻭﺍﻟﺘﻐﻴﺮﺍﺕ ﻓﻲ‬،‫ ﻭﻣﺪﺓ ﺍﻟﺘﻬﻮﻳﺔ ﺍﻟﻤﻴﻜﺎﻧﻴﻜﻴﺔ‬،‫ﻛﺎﻧﺖ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﺮﺋﻴﺴﻴﺔ ﻣﻌﺪﻝ ﺍﻟﻮﻓﻴﺎﺕ‬ .‫ ﻭﻣﺴﺘﻮﻳﺎﺕ ﺍﻟﺒﺮﻭﺗﻴﻦ ﺍﻟﻤﺘﻔﺎﻋﻞ ﺳﻲ‬،‫ﻣﺆﺷﺮﺍﺕ ﺍﻷﻭﻛﺴﺠﻴﻦ‬ ‫ ﻟﻢ ﻳﻜﻦ ﻫﻨﺎﻙ ﻓﺮﻕ ﺟﻮﻫﺮﻱ ﻓﻲ ﺍﻟﻮﻓﻴﺎﺕ ﻭﻣﺪﺓ ﺍﻟﺘﻬﻮﻳﺔ ﺍﻟﻤﻴﻜﺎﻧﻴﻜﻴﺔ ﺑﻴﻦ‬:‫ﺍﻟﻨﺘﺎﺋﺞ‬ ‫ ﺍﻟﻤﺘﻮﺳﻂ ) ﺍﻻﻧﺤﺮﺍﻑ‬،‫ ﺃﻳﺎﻡ ﻣﻦ ﺍﻟﺘﺪﺧﻞ‬5 ‫ ﺑﻌﺪ‬.‫ﻣﺠﻤﻮﻋﺎﺕ ﺍﻟﺘﺤﻜﻢ ﻭﺍﻟﺘﺪﺧﻞ‬ * Corresponding address: Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Behdari Q6 Street, Railway Square, Tehran, Iran. E-mail: h-hosami@sina.tums.ac.ir (H. Hosamirudsari) Peer review under responsibility of Taibah University. Production and hosting by Elsevier ) 47.28 ‫ﺍﻟﻤﻌﻴﺎﺭﻱ( ﻟـﻠﺒﺮﻭﺗﻴﻦ ﺍﻟﻤﺘﻔﺎﻋﻞ ﺳﻲ ﻭ ﻋﺪﺩ ﺍﻟﺼﻔﺎﺋﺢ ﺍﻟﺪﻣﻮﻳﺔ ﻛﺎﻥ‬ ‫ ﻣﻴﻜﺮﻭﻟﺘﺮ ﻓﻲ ﻣﺠﻤﻮﻋﺔ‬/  1000 (87.13 ) 195.73 ‫ ﻟﺘﺮ ﻭ‬/ ‫( ﻣﻠﻐﻢ‬38.86 /  1000 (68.03 ) 149.62 ‫ ﻟﺘﺮ ﻭ‬/ ‫( ﻣﻠﻐﻢ‬48.02 ) 75.52 ‫ﺍﻟﺘﺪﺧﻞ ﻭ‬ .‫ﻣﻴﻜﺮﻭﻟﺘﺮ ﻓﻲ ﻣﺠﻤﻮﻋﺔ ﺍﻟﺘﺤﻜﻢ ﻋﻠﻰ ﺍﻟﺘﻮﺍﻟﻲ‬ 19-‫ ﺍﺭﺗﺒﻂ ﺗﻨﺎﻭﻝ ﺟﺮﻋﺎﺕ ﻋﺎﻟﻴﺔ ﻣﻦ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ ﻓﻲ ﻣﺮﺿﻰ ﻛﻮﻓﻴﺪ‬:‫ﺍﻻﺳﺘﻨﺘﺎﺟﺎﺕ‬ ‫ ﻓﺈﻥ ﺗﺄﺛﻴﺮﻩ ﻋﻠﻰ ﻧﺘﺎﺋﺞ‬،‫ ﻭﻣﻊ ﺫﻟﻚ‬.‫ﺑﺎﻟﺘﻨﺎﻗﺺ ﻓﻰ ﻣﺴﺘﻮﻳﺎﺕ ﺍﻟﺒﺮﻭﺗﻴﻦ ﺍﻟﻤﺘﻔﺎﻋﻞ ﺳﻲ‬ .‫ﺍﻟﻤﺮﺿﻰ ﻟﻢ ﻳﻜﻦ ﻣﻠﺤﻮﻇﺎ‬ ‫؛ ﺍﻟﻤﻴﻼﺗﻮﻧﻴﻦ؛ ﺗﻨﺒﻴﺐ؛ ﻣﻌﺪﻝ ﺍﻟﻮﻓﻴﺎﺕ؛ ﺍﻟﻌﻼﺝ‬19-‫ ﻛﻮﻓﻴﺪ‬:‫ﺍﻟﻜﻠﻤﺎﺕ..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit